The onset of childbirth and the postpartum period are times when women with von Willebrand disease (VWD) are at an increased risk for excessive bleeding, exposing them to further, and in some instances, serious complications. While there exist therapies with VWD-specific indications, it is not uncommon for these patients to still experience excessive bleeding while receiving treatment. These scenarios are challenging as there is sparce clinical data and a subsequent lack of clear guidance on the optimal management of bleeding in these particular settings.
The von Willebrand factor in pregnancy (VIP) study was therefore developed to enhance understanding of how best to manage bleeding during delivery and the postpartum period in women with VWD. Investigators for this prospective, multicenter trial will focus on maintaining von Willebrand factor (VWF) levels at a specific target level using VWF replacement therapy, and assessing the impact on bleeding rates during and after childbirth.
The VIP study is being stewarded by a trio of experienced principal investigators including Drs. Jill Johnsen (Bloodworks and University of Washington), Barbara Konkle (University of Washington), and Dr. Peter Kouides (Mary M. Gooley Hemophilia Center and University of Rochester). The VIP Study is currently recruiting pregnant women in the U.S. above 18 years of age with VWD of any type.
An exciting component of the VIP is a new companion website, created to keep patients and healthcare professionals informed about the study. It will provide information on VIP’s design, patient eligibility, and locations of participating centers.
The site was officially launched on December 10th during an educational webinar that preceded the American Society of Hematology Annual Meeting.
Source: PR Newswire/The VIP Study, November 28, 2021